相似文献
1
Exploring New Frontiers: Innovations and Therapeutic Targets in Dermatology.
Int J Mol Sci. 2024 Jul 25;25(15):8102. doi: 10.3390/ijms25158102.
2
[Dermatology -- the most progressive discipline in medicine].
J Dtsch Dermatol Ges. 2015 Jul;13(7):617-9. doi: 10.1111/ddg.12764.
3
Innovations in dermatology.
Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):641-644. doi: 10.4103/0378-6323.190871.
4
Issues, changes, and opportunities for dermatology in the new millennium: innovations and changes in understanding the biology of the skin that will affect dermatology in the next century.
Arch Dermatol. 2000 Jan;136(1):57-9. doi: 10.1001/archderm.136.1.57.
5
High-tech dermatology.
Eur J Dermatol. 2007 Mar-Apr;17(2):178-80. doi: 10.1684/ejd.2007.0146. Epub 2007 Mar 2.
6
What's new in '92--the past decade of pediatric dermatology.
Pediatr Dermatol. 1992 Dec;9(4):390-6. doi: 10.1111/j.1525-1470.1992.tb00640.x.
7
Innovations in Pediatric Dermatology.
Pediatr Ann. 2016 Aug 1;45(8):e278-9. doi: 10.3928/19382359-20160720-04.
8
Nurture Indian dermatology innovations as man-maximum, machine-minimum research.
Indian J Dermatol Venereol Leprol. 2017 Nov-Dec;83(6):684-686. doi: 10.4103/ijdvl.IJDVL_26_17.
9
A report on the 69th annual meeting of the society for investigative dermatology.
Drug News Perspect. 2009 Sep;22(7):429-33. doi: 10.1358/dnp.2009.22.7.1406172.
10
New developments and technologies in dermatology.
Lasers Med Sci. 2007 Jun;22(2):65. doi: 10.1007/s10103-006-0429-3.
本文引用的文献
1
The potential of RNA therapeutics in dermatology.
Ann Acad Med Singap. 2024 Feb 28;53(2):113-116. doi: 10.47102/annals-acadmedsg.2023316.
2
Successful treatment of erythema nodosum leprosum with upadacitinib and roflumilast.
Int J Dermatol. 2025 Jan;64(1):164-166. doi: 10.1111/ijd.17293. Epub 2024 Jun 6.
3
The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review.
Inflamm Res. 2024 Aug;73(8):1311-1332. doi: 10.1007/s00011-024-01900-w. Epub 2024 Jun 5.
4
Shedding Light on Acne Scars: A Comprehensive Review of CO2 vs. Erbium-Doped Yttrium Aluminium Garnet (Er:YAG) Laser Therapy.
Cureus. 2024 Apr 3;16(4):e57572. doi: 10.7759/cureus.57572. eCollection 2024 Apr.
5
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Lancet Rheumatol. 2022 Apr;4(4):e282-e292. doi: 10.1016/S2665-9913(21)00317-9. Epub 2022 Feb 3.
6
Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus.
J Am Acad Dermatol. 2023 Jul;89(1):171-173. doi: 10.1016/j.jaad.2023.02.044. Epub 2023 Mar 5.
7
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Lancet. 2023 Mar 25;401(10381):1001-1010. doi: 10.1016/S0140-6736(22)02607-1. Epub 2023 Feb 24.
8
Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action.
Clin Cosmet Investig Dermatol. 2022 Nov 16;15:2495-2506. doi: 10.2147/CCID.S374122. eCollection 2022.
9
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024.
10
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
Ann Rheum Dis. 2022 Oct 12;81(11):1556-1563. doi: 10.1136/ard-2022-222858.
Zotero 插件